| Literature DB >> 32104018 |
Mohammadmahdi Karimi-Yazdi1, Zohreh Ghalavand1, Mahdi Shabani2, Hamidreza Houri3, Mehrzad Sadredinamin1, Marzieh Taheri1, Gita Eslami1.
Abstract
BACKGROUND: Shigella continues to be important causes of acute pediatric diarrhea worldwide. Shigella produces numerous virulence factors involved in colonization and invasion into epithelial cells which eventually result in the disease. The present study was conducted to evaluate the prevalence of virulence genes and to investigate antibiotic resistance profiles among Shigella isolates obtained from pediatric patients in Iran.Entities:
Keywords: Shigella; ipaB; ipaH; type III secretion system; virA; virulence factors
Year: 2020 PMID: 32104018 PMCID: PMC7025676 DOI: 10.2147/IDR.S238559
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Antimicrobial Resistance of Shigella Isolates from Pediatric Patients in Iran
| Antibiotics | Total of | ||||
|---|---|---|---|---|---|
| CTX | 70 (63.1) | 12 (42.8) | 2 (100.0) | 84 (59.6) | |
| NA | 104 (93.7) | 10 (35.7) | 2 (100.0) | 116 (82.3) | |
| AMP | 74 (66.7) | 27 (96.4) | 2 (100.0) | 103 (73.0) | |
| SXT | 111 (100.0) | 26 (92.8) | 0.03 | 2 (100.0) | 139 (98.5) |
| LEV | 12 (10.8) | 4 (14.3) | 0.521 | 0 (00.0) | 16 (11.3) |
| CFM | 69 (62.1) | 13 (46.4) | 2 (100.0) | 84 (59.6) | |
| MN | 86 (77.5) | 7 (25) | 0 (00.0) | 93 (65.9) | |
| CIP | 3 (2.7) | 5 (17.8) | 0 (00.0) | 8 (5.7) | |
| AZT | 65 (58.6) | 2 (7.1) | 0 (00.0) | 67 (47.5) | |
| MDR | 86 (77.5) | 13 (46.4) | 2 (100.0) | 101 (71.6) |
Note: Statistically significant values (P<0.05) are presented in bold.
Abbreviations: AMP, ampicillin; AZT, azithromycin; CFM, cefixime; CIP, ciprofloxacin; CTX, cefotaxime; LEV, levofloxacin; NA, nalidixic acid; MDR, multidrug resistance; MN, minocycline; SXT, trimethoprim-sulfamethoxazole.
Antibiotic Resistance Profiles of Shigella spp. from Pediatric Diarrhetic Patients
| Antibiotics Profiles | Age | Total No. | |||||
|---|---|---|---|---|---|---|---|
| 2 Months to 5 Years | 6 to14 Years | ||||||
| CIP/AZT/CFM/LEV/MN/CTX/NA/AM/SXT | 4 | _ | _ | 5 | _ | _ | 9 |
| AZT/CFM/CTX/MN/NA/AM/SXT/LEV | 20 | _ | _ | 21 | _ | _ | 41 |
| AZT/CFM/MN/CTX/NA/AM/SXT | _ | _ | _ | 3 | _ | _ | 3 |
| SXT/CTX/NA/MN/AM/ | 2 | 5 | 1 | _ | 1 | _ | 9 |
| SXT/MN/NA | 17 | _ | _ | 7 | _ | _ | 24 |
Abbreviations: AMP, ampicillin; AZT, azithromycin; CFM, cefixime; CIP, ciprofloxacin; CTX, cefotaxime; LEV, levofloxacin; NA, nalidixic acid; MDR, multidrug resistance; MN, minocycline; SXT, trimethoprim-sulfamethoxazole.
Figure 1The minimum inhibitory concentration (MIC) of azithromycin for clinical isolates of Shigella recovered from pediatric patients in Tehran, Iran.
Distribution of Virulence Factor Genes in 141 Shigella spp. Isolated from Pediatric Patients
| Virulence Genes | S. sonnei No. (%), n = 111 | S. flexneri No. (%), n = 28 | S. boydii No. (%), n = 2 | Total of Shigella Strains No. (%), n = 141 |
|---|---|---|---|---|
| 111 (100.0) | 28 (100.0) | 2 (100.0) | 141 (100.0) | |
| 101 (90.1) | 28 (100.0) | 2 (100.0) | 131 (92.9) | |
| 105 (94.6) | 28 (100.0) | 2 (100.0) | 135 (95.7) | |
| 103 (92.8) | 28 (100.0) | 2 (100.0) | 133 (94.3) | |
| 88 (79.3) | 24 (85.7) | 2 (100.0) | 114 (80.8) | |
| 107 (96.4) | 26 (92.8) | 2 (100.0) | 135 (95.7) | |
| 103 (92.8) | 27 (96.4) | 2 (100.0) | 132 (93.6) |
Virulence Determinant Profiles of the Shigella spp. Isolated from Pediatric Patients
| Shigella spp. | ipaH | ipaB | ipaC | ipaD | ipgD | Sen | virA | No. (%) |
|---|---|---|---|---|---|---|---|---|
| + | + | + | + | + | + | + | 86 (77.5) | |
| + | + | + | + | – | + | + | 12 (10.8) | |
| + | + | – | + | – | + | + | 2 (1.8) | |
| + | – | + | – | – | + | – | 3 (2.7) | |
| + | – | – | – | – | + | + | 2 (1.8) | |
| + | – | – | + | – | – | – | 2 (1.8) | |
| + | + | + | – | + | – | – | 1 (0.9) | |
| + | – | + | + | + | + | + | 1 (0.9) | |
| + | – | + | – | – | + | + | 1 (0.9) | |
| + | – | + | – | – | – | – | 1 (0.9) | |
| + | + | + | + | + | + | + | 24 (85.7) | |
| + | – | + | + | – | + | + | 1 (86.0) | |
| + | + | + | + | – | – | + | 1 (3.5) | |
| + | + | + | + | – | + | + | 1 (3.5) | |
| + | + | + | – | – | – | + | 1 (3.5) | |
| + | + | + | + | + | + | + | 2 (100.0) |